Empagliflozin Add on to Linagliptin Study in Japanese Patient With Type 2 Diabetes Mellitus

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 275 participants.

Also called NCT02453555

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 275 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT02453555
Other papers using this trial's data
  • Empagliflozin as add-on to linagliptin in a fixed-dose combination in Japanese patients with type 2 diabetes: Glycaemic efficacy and safety profile in a 52-week, randomized, placebo-controlled trial Diabetes, obesity & metabolism, 2018-09 DOI, PubMed 29766636, PMC6099460 In the PMC Open Access subset under CC BY-NC.

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
Japan (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT02453555. Randomized; double masking; primary purpose treatment. Start 2015-05-14 (actual); primary completion 2016-08-26 (actual). Results posted on 2019-02-15.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Empagliflozin Add on to Linagliptin Study in Japanese Patient With Type 2 Diabetes Mellitus
Condition
Diabetes Mellitus, Type 2
Intervention (Drug)
Linagliptin
Intervention (Drug)
Empagliflozin placebo + linagliptin placebo low dose
Intervention (Drug)
Empagliflozin + linagliptin low dose
Intervention (Drug)
Linagliptin placebo
Intervention (Drug)
Empagliflozin + linagliptin high dose
Intervention (Drug)
Empa + lina highdose placebo
Lead sponsor
Boehringer Ingelheim (class: industry)
Collaborator
Eli Lilly and Company (class: industry)

Record details

Record id
cardio:ct-nct02453555
Content hash
20e02a321d8e1ca436871e79c1867a77271320e401cff77b1b76e27a269e0b69